No Data
No Data
CARSGEN-B: INTERIM REPORT 2024
gtja: Maintains a "shareholding" rating for SciClone Pharmaceuticals-B (02171), Saikai Capital is expected to achieve terminal sales of 0.1 billion yuan for the whole year.
gtja predicts that the commercialization orders of Keji Pharmaceutical-B (02171) for Saizhaoze in 2024 will correspond to a sales volume of 0.1 billion RMB in the terminal market, with 87 orders (1.15 million per person).
Kangji Pharmaceutical-B (2171.HK): Expect significant volume expansion for Saikai Ze CT041 clinical progress smooth
Report Summary: Saikaize has good sales and is expected to achieve terminal sales of 0.1 billion yuan (87 units) for the whole year, with actual orders exceeding one hundred units. CT041, a treatment for gastric cancer, is expected to submit an NDA for 25HI, and the company's long-term development is bullish, maintaining...
Keji Pharmaceutical - B (02171.HK): Saikai Ze's commercialization is progressing smoothly. Homologous CAR-T has entered clinical research.
Koji Pharmaceutical released its 2024 interim performance. The company achieved revenue of 6 million yuan in the first half of 2024, with a net loss of 352 million yuan, compared to a loss of 404 million yuan in the same period of 2023; achieved an adjusted net loss of 3.42 billion yuan.
CARsgen Announces 2024 Interim Results
CARsgen Therapeutics Holdings Books Narrower Attributable Loss in H1
No Data
No Data